Contents lists available at ScienceDirect

Phytochemistry Letters

journal homepage: www.elsevier.com/locate/phytol

Novel *seco*-phenanthroquinolizidine alkaloids from Indonesian *Boehmeria virgata*

Abdul Rahim^{a,b}, Yohei Saito^a, Katsunori Miyake^c, Masuo Goto^d, Kyoko Nakagawa-Goto^{a,d,*}

^a School of Pharmaceutical Sciences, College of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan

^b Department of Pharmaceutical Sciences and Technology, Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia

^c School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, 192-0392, Japan

^d Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, 27599-7568, United States

ARTICLE INFO

Keywords: Boehmeria virgata Seco-phenanthroquinolizidine Alkaloid Antiproliferative activity

ABSTRACT

Two novel *seco*-phenanthroquinolizidine alkaloids, (-)-(14aR,15R)-hydroxyjulandine (1) and (+)-(S)-3-O-desmethyljulandine (2), together with eleven known compounds (3-13) were isolated from the leaves of Indonesian *Boehmeria virgata*. The structures of these compounds were assigned based on the interpretation of 1D/2D NMR and HRMS data. The absolute configurations of *seco*-phenanthroquinolizidines 1 and 2 were determined from their ECD spectra by comparison with the known phenanthroquinolizidine 3. The isolated *seco*-phenathroquinolizidines 1–3 were evaluated for antiproliferative activity against five tumor cell lines. Compound 3 exhibited potent cytotoxic activity, while 1 and 2 were not active against all tested cell lines.

1. Introduction

Phenanthroquinolizidine compounds, a subtype of quinolizidine alkaloids, are a small group of herbal metabolites found in several plant families, such as Urticaceae (Hart et al., 1968); (Cai et al., 2006); (Hoffmann et al., 1978); (Krmpotic et al., 1972); (Al-Shamma et al., 1982); (Doan Thi Thuy et al., 2019); (Luo et al., 2003), Vitaceae (Saifah et al., 1983), Lauraceae (Hoffmann et al., 1978), and Acanthaceae (Abdel-Şattar et al., 2020). An overview of the literature (Jia et al., 2020) and the latest report by Abdel-Şattar et al. (2020) revealed no more than ten naturally occurring phenanthroquinolizidine alkaloids with promising biological properties, including cytotoxic (Hoffmann et al., 1978); (Doan Thi Thuy et al., 2019); (Luo et al., 2003), antiviral (Krmpotic et al., 1972), antimicrobial (Al-Shamma et al., 1982), and antimalarial (Abdel-Şattar et al., 2020) have been reported.

Boehmeria virgata (G. Forst.) Guill. (Urticaceae), locally known as "Parangromang", is a medicinal plant traditionally used by the Makassar ethnic group in South Sulawesi, Indonesia to treat cancer diseases (Manggau et al., 2018); (Wardihan et al., 2013). Previous studies reported that an ethanolic extract of *B. virgata* leaves exhibited cytotoxic activity against HeLa, WiDr, and T4T7D cell lines (Wardihan et al., 2013) and alkaloid compounds were predicted as the pharmacologically

active substances (Manggau et al., 2018). Although no details on isolated active constituents of this plant were subsequently reported, alkaloid components especially phenanthroquinolizidine analogues have been isolated from related species including B. pannosa Nakai & Satake ex Oka (Cai et al., 2006), B. cylindrica (L.) Sw. (Al-Shamma et al., 1982), B. siamensis Craib (Luo et al., 2003), B. caudata Sw. (Hoffmann et al., 1978), and B. rugolosa Wedd. (Semwal et al., 2009). Furthermore, triterpenoid compounds, such as boehmerone and boehmerol (Oyarzún et al., 1986), as well as a lignan, boehmenan (Takemoto et al., 1975), were obtained from *B. excelsa* (Bertero ex Steud.) Wedd. and *B. tricuspis* (Hance) Makino, respectively. The isolations of flavonoid glycosides (Semwal et al., 2009) and other compounds (Doan Thi Thui et al., 2018) have also been reported. In our continuing phytochemical studies of Indonesian plants collected in South Sulawesi (Yamashita et al., 2020); (Rahim et al., 2020); (Rahim et al., 2018), we herein report the isolation and structure elucidation of two novel seco-phenanthroquinolizidine alkaloids 1 and 2, along with eleven known compounds (3-13) from the Indonesian plant B. virgata, as well as the antiproliferative activity of the isolated seco-phenanthroquinolizidines 1–3.

https://doi.org/10.1016/j.phytol.2021.08.003

Received 19 June 2021; Received in revised form 29 July 2021; Accepted 6 August 2021







^{*} Corresponding author at: School of Pharmaceutical Sciences, College of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.

E-mail address: kngoto@p.kanazawa-u.ac.jp (K. Nakagawa-Goto).

^{1874-3900/} \odot 2021 Phytochemical Society of Europe. Published by Elsevier Ltd. All rights reserved.

2. Results and discussion

Leaves of *B. virgata* were extracted with methanol, and the extract was further partitioned and fractionated using various chromatographic techniques to give two new *seco*-phenanthroquinolizidine alkaloids, (–)-(14aR,15R)-hydroxyjulandine (1) and (+)-(*S*)-3-*O*-desmethyljulandine (2) (Fig. 1). Eleven known compounds (Figure S1, Supporting Information), including (–)-(*R*)-julandine (3) (Suzuki et al., 1995), (–)-cryptopleurine (4) (Kim et al., 2004), ixerol B (5) (Hu and Wang, 2013), 4-oxo- β -ionol (6) (Hartman et al., 1988), (3*R*,6*R*,7*E*)-3-hydroxy-4,7-megastigmadien-9-one (7), (–)-3-hydroxy- β -ionone (8) (Machida and Kikuchi, 1996), (–)-dehydrovomifoliol (9) (Mori, 1974), (–)-3-oxo- α -ionone (10) (Ito et al., 1997), methyl trans-ferulate (11) (Song et al., 2008), *p*-coumaric acid methyl ester (12) (Seifert and Unger, 1994), and (*S*)-5-methoxypyrrolidin-2-one (13) (Song et al., 2008), were also isolated and elucidated by comparison of their spectroscopic data with those in the literature.

Compound **1** was isolated as a pale-yellow oil and showed a positive response with Dragendorff reagent. The molecular formula, C₂₄H₃₀NO₄, was determined based on a protonated molecular ion peak at m/z396.2176 [M+H]⁺, (calcd 396.2175) by HRMS. The ¹H NMR data of **1** (Table 1) indicated the presence of three methoxy groups at $\delta_{\rm H}$ 3.58 (3H, s, OCH₃-2), 3.71 (3H, s, OCH₃-6), and 3.81 (3H, s, OCH₃-3). A 1,2,4trisubstituted phenyl ring (ring-A) was postulated from proton signals at $\delta_{\rm H}$ 6.53 (1H, d, J = 1.7 Hz, H-1), 6.70 (1H, dd, J = 1.7, 8.3 Hz, H-4a), and 6.72 (1H, d, J = 8.3 Hz, H-4), while a 1,4-disubstituted benzene ring (ring-B) was proposed from proton signals at $\delta_{\rm H}$ 6.67 (2H, dd, J = 2.1, 8.6 Hz, H-5 and H-7) and 6.92 (2H, dd, J = 2.1, 8.6 Hz, H-4a and H-8). A signal at $\delta_{\rm H}$ 4.40 (1H, dd, J= 1.7, 7.6 Hz, H-15) was characterized as a hydroxylated methine. The ¹³C NMR data (Table 1) showed 24 carbon signals (two overlapped carbon signals at $\delta_{\rm C}$ 129.3 and 113.3), which corresponded to three methoxy carbons (δ_{C} 55.1, 55.6, and 55.7), five methylene carbons ($\delta_{\rm C}$ 59.7, 55.4, 30.6, 25.3, and 23.9), nine methine carbons including seven aromatic (δ_{C} 129.3, 129.3, 121.4, 113.3, 113.3, 113.5, and 110.8) and two carbons bearing oxygen and nitrogen ($\delta_{\rm C}$ 73.8 and 64.4, respectively), as well as seven non-hydrogenated olefinic and aromatic carbons (Sc 158.1, 148.4, 147.7, 134.5, 133.8, 132.5, and 130.1) based on the HMQC and DEPT spectra. In the HMBC spectrum of 1 (Fig. 2), the correlations of H-1 with C-3/C-4a/C-15a and H-4 with C-2/C-15b characterized a 1,2,4-trisubstituted phenyl ring-A linked to a quinolizidine moiety at C-15a, while the correlations of H-4b/H-8 with C-6/C-8b and H5/H7 indicated a C-8a 1,4-disubstituted benzene ring-B connected at C-8b. Based on these data and the presence of COSY correlations encompassing H-11 to H-15, compound 1 is likely a seco-phenanthroquinolizidine alkaloid. When the NMR spectroscopic data were compared with those of the known phenathroquinolizidine, (-)-14aRjulandine (3) (Suzuki et al., 1995), differences were observed at only the C-14, C-14a, and C-15 positions and an additional methine signal at $\delta_{\rm H}$ 4.40 (1H, dd, J = 1.7, 7.6 Hz, H-15) was present. These findings together



Table I	
¹ H and ¹³ C NMR S	pectroscopic Data of 1 and 2.

	1		2		
Position	$\delta_{ m H} \left(J \text{ in Hz} \right)^{a}$	$\delta_{ m C}{}^a$	$\delta_{\rm H} \left(J \text{ in Hz} \right)^a$	$\delta_{ m C}{}^{^{b}}$	
1	6.53 d (1.7)	113.5	6.41 d (1.7)	112.4	
2		148.4		145.6	
3		147.7		143.8	
4	6.72 d (8.3)	110.8	6.72 d (8.2)	113.7	
4a	6.70 dd (1.7, 8.3)	121.4	6.61 dd (1.7, 8.2)	121.3	
4b	6.92 dd (2.1, 8.6)	129.3	6.97 dd (1.8, 8.7)	130.2	
5	6.67 dd (2.1, 8.6)	113.3	6.69 dd (1.8, 8.7)	113.4	
6		158.1		157.9	
7	6.67 dd (2.1, 8.6)	113.3	6.69 dd (1.8, 8.7)	113.4	
8	6.92 dd (2.1, 8.6)	129.3	6.97 dd (1.8, 8.7)	130.2	
8a		132.5		133.3	
8b		133.8		131.4	
9	a. 3.29 d (16.5)	59.7	a. 3.02 d (16.5)	60.4	
	b. 3.37 d (16.5)		b. 3.56 d (16.5)		
11	a. 2.17 m	55.4	a. 2.09 m	55.6	
	b. 3.01 m		b. 3.06 m		
12	1.69 m	25.3	1.71 m	25.9	
13	a. 1.37 overlap	23.9	a. 1.32 m	24.4	
	b. 1.86 m		b. 1.79 m		
14	a. 1.36 overlap	30.6	a. 1.31 m	33.3	
	b. 2.31 m		b. 1.83 m		
14a	2.23 m	64.4	2.22 m	57.9	
15	4.40 dd (1.7, 7.6)	73.8	a. 2.31 m	39.6	
			b. 2.51 m		
15a		134.5		131.3	
15b		130.1		133.9	
OCH ₃ -2	3.58 s	55.6	3.53 s	55.6	
OCH ₃ -3	3.81 s	55.7			
OCH ₃ -6	3.71 s	55.1	3.72	55.2	

^{a1}H NMR: 600 MHz in CDCl₃, ¹³C NMR: 100 MHz in CDCl₃.

^{b13}C NMR: 150 MHz in CDCl₃.

with the fact that the molecular weight of **1** is 16 amu more than that of **3** suggested that **1** is a hydroxylated julandine analogue. A NOESY correlation between H-14a and H-9*a* indicated an *a* orientation for H-14a (Fig. 3). Also, correlations of H-15 with H-14*a*, H-14a, and H-1 indicated OH-15 and H-14a *trans* to each other and in axial positions. These NOESY correlations also supported the connection of ring-A to C-15a. Compound **1** exhibited a negative optical rotation, $[\alpha]_D^{23}$ -137.6 (CHCl₃, *c* 0.14), and a negative Cotton effect at 284 nm in the CD spectrum, which were the same as those of (-)-*R*-julandine (**3**, $[\alpha]_D^{23}$ -57.9 (CHCl₃, *c* 0.16)) isolated in this study (Fig. 4). The data indicated that **1** and **3** have the same *R*-orientation at C-14a. Therefore, compound **1** was determined to be (-)-(14a*R*,15*R*)-hydroxyjulandine.

Compound **2** was obtained as a pale-yellow oil. In the HRMS of **2**, a protonated molecular ion peak at m/z 366.2073 [M+H]⁺ (calcd 366.2069) indicated a molecular formula of C₂₂H₂₈NO₃, which is 30 amu less than that of **1** indicating loss of OCH₂. The ¹H NMR data of **2** were like those of **1**, except for the absence of the hydroxylated methine





Fig. 1. Structures of compounds 1 and 2 isolated from B. virgata leaves.



Fig. 2. ¹H-¹H COSY (bold lines) and selected key HMBC (arrows) correlations of compounds 1 and 2.



Fig. 3. Key NOESY correlations (dotted arrows) of compounds 1 and 2.



Fig. 4. Experimental ECD spectra of compounds 1-3 in MeOH.

signal ($\delta_{\rm H}$ 4.40) found in 1 and the presence of two, rather than three, methoxy signals in 2. The differences in the ¹³C NMR data (Table 1) of 1 and 2 at C-2, C-3, and C-4 indicated that a methoxy group on the 1,2,4-trisubstituted phenyl ring-A of 1 was changed to a hydroxy group in 2. The HMBC correlations of the methoxy signals at $\delta_{\rm H}$ 3.52 (3H, s) with $\delta_{\rm C}$ 145.6 (C-2), $\delta_{\rm H}$ 6.41 (d, J = 1.7 Hz, H-1) with $\delta_{\rm C}$ 143.8 (C-3)/ $\delta_{\rm C}$ 121.3 (C-4a), $\delta_{\rm H}$ 6.72 (d, J = 8.2 Hz, H-4) with $\delta_{\rm C}$ 145.6 (C-2)/ $\delta_{\rm C}$ 133.9 (C-15b), and $\delta_{\rm H}$ 3.72 (3H, s) with $\delta_{\rm C}$ 157.9 (C-6) suggested that 2 is a 3-O-desmethyl analogue of julandine. Compound 2 showed a positive optical rotation with $[\alpha]_{\rm D}^{23}$ +44.1 (CHCl₃, *c* 0.03) and positive Cotton effect at 284 nm in CD spectrum (Fig. 4). Based on these results, compound 2 has an *S*-configuration at C-14a and was determined to be (+)-(*S*)-3-O-desmethyljulandine.

The *seco*-phenanthroquinolizidines **1**, **2**, and **3** were evaluated for their antiproliferative activity against five human tumor cell lines (HTCLs), A549 (lung cancer), MCF-7 (breast cancer: estrogen receptor

(ER) positive and HER2 negative), MDA-MB-231 (breast cancer: ER, progesterone receptor (PR), and HER2 negative), KB (epidermoid carcinoma: HeLa derivative) and KB-VIN (vincristine resistant KB subline: P-gp-over-expressing). The known seco-phenanthroquinolizidine, (R)julandine (3), showed potent cytotoxicity against all cell lines including MDR (KB-VIN) (Table 2), while the newly identified seco-phenanthroquinolizidines 1 and 2 displayed no activity. The greater potency of 3 compared with 1 was consistent with prior reports that hydroxylation at C-15 of the phenanthroquinolizidine skeleton decreases cytotoxicity (Cai et al., 2006). Although compound 2 was inactive, the related pileamartine D with a bond between C-4a and C-4b showed selective cytotoxic activity in a recent study (Doan Thi Thuy et al., 2019) suggesting that a rigid phenanthrene structure is beneficial for cytotoxicity. In addition, although cryptopleurine (4) was not tested in this study due to insufficient quantity, it exhibits nanomolar cytotoxic activity against many HTCLs as reported in other studies (Doan Thi Thuy et al., 2019); (Banwell et al., 2006). Similarly, reduced cytotoxicity was previously reported for some seco-phenanthroquinolizidine (Banwell et al., 2006) and phenanthroindolizidine derivatives (Lykkeberg et al., 2002); (Stærk et al., 2000)

3. Experimental

3.1. General experimental

Optical rotations were measured on a JASCO P-2200 digital polarimeter in CHCl₃. NMR spectra were recorded on JEOL JNM-ECS400 and JNM-ECA600 NMR spectrometers with tetramethylsilane as an internal standard. Chemical shifts (δ) are stated in part per million (ppm). HRMS data were obtained from JMS-700 (FAB) mass spectrometer. Analytical and preparative TLC were performed on precoated silica gel 60 F₂₅₄ plates (0.25 or 1 mm thickness; Merck) and NH₂ silica gel F₂₅₄ (0.5 mm; Wako). Column chromatography was performed with silica gel 60 N Table 0

Antiproliferative Da	ata of Compounds 1–3.

compound	cell lines $(IC_{50} \mu M)^a$					
	A549	MDA-MB-231	MCF-7	KB	KB-VIN	
1	24.4 ± 0.8	28.8 ± 1.2	$\textbf{36.2} \pm \textbf{1.8}$	31.8 ± 0.3	44.5 ± 3.0	
2	>40	>40	>40	>40	>40	
3	0.8 ± 0.1	0.9 ± 0.01	4.6 ± 0.3	3.6 ± 0.4	$\textbf{4.5} \pm \textbf{0.4}$	
PXL (<i>n</i> M) ^b	$\textbf{6.4} \pm \textbf{0.1}$	$\textbf{7.7} \pm \textbf{0.5}$	$\textbf{7.6} \pm \textbf{0.5}$	5.2 ± 0.1	1538.4 ± 116.5	

^a Antiproliferative activity is stated as IC₅₀ values for each cell line, the concentration of compound that caused 50 % reduction relative to untreated cells evaluated by the SRB assay, mean \pm SD (n = 6).

^b The IC₅₀ of paclitaxel (PXL) is stated in *n*M.

(spherical, 63–210 μ m, neutral, Kanto Chemical). Analytical and reversed-phase preparative TLC (PTLC) was conducted on Silica gel 60 RP-18 F254S (0.25 mm, Merck). All cell lines were obtained from the Lineberger Comprehensive Cancer Center (UNC–CH) or from ATCC, except KB-VIN, which was obtained from Professor Y.-C. Cheng (Yale University).

3.2. Plant material

Leaves of *B. virgata* were collected at Lengkese Village, Parigi Subsdistrict, Gowa, South Sulawesi, Indonesia in November 2019 and authenticated by Djoko Santoso, Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia. A voucher specimen was deposited in the Pharmacognosy-Phytochemistry Laboratory, Hasanuddin University (2019_AR_FFUH_01).

3.3. Extraction and isolation compounds

Air-dried leaves of B. virgata (1.45 kg) were powdered and extracted three times (8.5 L for each time) with MeOH at room temperature for 48 h. The volatile solvent was evaporated to afford a crude MeOH extract (90.8 g). The MeOH extract was further partitioned between nhexane and MeOH-H₂O (9:1) to give n-hexane and MeOH-H₂O extracts, 69.8 g and 20.4 g, respectively. The MeOH-H₂O extract in EtOAc (250 mL) was subjected to ultrasound sonication for 15 min to separate EtOAc soluble and insoluble parts. The same process was repeated five times on the insoluble part to give an EtOAc soluble part (1.86 g) and insoluble material (18.45 g). The EtOAc soluble part (1.8 g) was subjected to column chromatography (CC) on a silica gel eluting with nhexane-acetone (10:1, 5;1, 1:1, 1:2, 1:5, v/v), acetone 100 %, and MeOH 100 % to give 12 fractions (FA-FL). Fraction J (291 mg) was rechromatographed by silica gel CC eluted successively with CHCl3-MeOH (40:1, 30:1, 25:1, 20:1, 10:1, v/v) and MeOH 100 % to afford nine subfractions (J1-J9). The subfraction J4 (18.5 mg) was separated by NH₂ silica gel PTLC developed with *n*-hexane–acetone (3:1, v/v) to give compounds 3 (3.1 mg), 4 (0.5 mg), and 1 (6.8 mg). Compounds 2 (0.7 mg) and 6 (2.4 mg) were isolated from subfractions J6 and J7, respectively, by NH₂ silica gel PTLC developed with CHCl₃-MeOH (20:1, v/v). Repeated purifications of subfraction J5 by NH₂ silica gel PTLC developed with CHCl3-MeOH (25:1, v/v) gave compound 5 (2.3 mg). Fraction I (500 mg) was further fractionated with reversed-phased medium pressure liquid chromatography (MPLC) eluted with MeOH-H2O (4:1, v/v), MeOH 100 %, and acetone to give 9 subfractions, I1-I9. Repeated chromatography of subfraction I2 (188.6 mg) by silica gel CC eluting with *n*-hexane–EtOAc (5:1, 4:1, 3:1, 1:1, 1:5, v/v), EtOAc 100 %, and MeOH 100 % yielded 15 further subfractions (I2A-I2O). Compounds 7 and 8 were obtained from subfraction I2E as a mixture (3.0 mg). Compound 9 (1.6 mg) was isolated from subfraction I2G (4.7 mg) by PTLC on silica gel eluted with *n*-hexane–EtOAc (2:1, v/v). A mixture (3.1 mg) of 10 and 11 was also obtained from subfraction I2H (11.3 mg) by reversed-phase PTLC eluted with MeOH-H₂O (3:1, v/v). Subfraction I2K was separated by the repeated reversed-phase PTLC eluted with MeOH-H₂O (2:1, v/v) and normal phase PTLC eluted with nhexane–EtOAc (2:1, v/v) to give compounds 12 (1.7 mg) and 13 (0.9 mg).

3.3.1. (-)-(14aR,15R)-hydroxyjulandine (1)

Pale-yellow oil; $[\alpha]_D^{23}$ –137.6 (CHCl₃, *c* 0.14); ECD (*c* 21 µg/mL, CH₃OH) $\Delta \epsilon_{284}$ –3.91, $\Delta \epsilon_{310}$ +1.24; ¹H NMR (CDCl₃, 600 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Tables 1 and 2; HR-FAB-MS *m/z* 396.2176 [M+H]⁺, (calcd for C₂₄H₃₀NO₄, 396.2175).

3.3.2. (+)-(14aS)-3-O-desmethyljulandine (2)

Pale-yellow oil; $[\alpha]_D^{23}$ +44.1 (CHCl₃, *c* 0.03); ECD (*c* 40 µg/mL, CH₃OH) $\Delta \epsilon_{284}$ +7.88, $\Delta \epsilon_{307}$ -4.43; ¹H NMR (CDCl₃, 600 MHz) and ¹³C NMR (CDCl₃, 150 MHz), see Tables 1 and 2; HR-FAB-MS *m/z* 366.2073 [M+H]⁺, (calcd for C₂₃H₂₈NO₃, 366.2069).

3.4. Antiproliferative activity assay

The antiproliferative activity assay using five human tumor cell lines, including A549 (lung carcinoma), MDA-MB-231 (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, HER2-negative breast cancer), MCF-7 (ER-positive, HER2-negative breast cancer), KB (epidermoid carcinoma, HeLa derivative), and KBVIN (vincristine resistant KB subline: P-gp-over-expressing) as previously presented (Saito et al., 2021). Briefly, 4000 - 12 000 freshly trypsinized cells were seeded in 96-well microtiter plates with each test compound prepared in DMSO, which were cultured for 72 h. The treated cells were fixed in 10 % trichloroacetic acid followed by staining with 0.04 % sulforhodamin B. The highest concentration of vehicle (DMSO) was 0.1 % v/v, which displayed no effect on cell growth. Paclitaxel (Sigma-Aldrich, purity >95 %) was used as a reference compound. The mean IC₅₀ is the concentration of compound that inhibited cell growth by 50 % compared with a vehicle control under the experimental conditions used and is the average from at least three independent experiments with duplicate samples (n = 6).

Declaration of Competing Interest

The authors declare no competing financial interest.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgements

We thank Dr. Djoko Santoso (Universitas Gadjah Mada, Indonesia) for the botanical identification of the plant material. We also appreciate the critical comments, suggestions, and editing of the manuscript by Dr. Susan L. Morris-Natschke (UNC–CH). This work was supported by JSPS KAKENHI grant number 16H05811 awarded to K.N.G.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.phytol.2021.08.003.

References

- Abdel-Şattar, E., Abdallah, H.M., El-Mekkawy, S., Ichino, C., Kiyohara, H., Yamada, H., 2020. Antimalarial alkaloid from *Hypoestes forskaolii*. Exp. Parasitol. 211, 107851 https://doi.org/10.1016/j.exppara.2020.107851.
- Al-Shamma, A., Drake, S.D., Guagliardi, L.E., Mitscher, L.A., Swayze, J.K., 1982. Antimicrobial alkaloids from *Boehmeria cylindrica*. Phytochemistry 21, 485–487. https://doi.org/10.1016/S0031-9422(00)95304-4.
- Banwell, M.G., Bezos, A., Burns, C., Kruszelnicki, I., Parish, C.R., Su, S., Sydnes, M.O., 2006. C8c–C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties. Bioorg. Med. Chem. Lett. 16, 181–185. https://doi.org/10.1016/j.bmcl.2005.09.032.
- Cai, X.F., Jin, X., Lee, D., Yang, Y.T., Lee, K., Hong, Y.S., Lee, J.H., Lee, J.J., 2006. Phenanthroquinolizidine alkaloids from the roots of *Boehmeria pannosa* potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. J. Nat. Prod. 69, 1095–1097. https://doi.org/10.1021/np060081y.
- Doan Thi Thui, A., Trinh Thi Thanh, V., Doan Thi Mai, H., Litaudon, M., Tram, L.H., Pham, V.C., 2018. Chemical constituents of *Boehmeria holosericea* Blume (Urticaceae). Vietnam J. Chem. 56, 172–175. https://doi.org/10.1002/ vich.201800008.
- Doan Thi Thuy, A., Trinh Thi Thanh, V., Doan Thi Mai, H., Le, H.T., Litaudon, M., Nguyen, V.H., Chau, V.M., Pham, V.C., 2019. Cytotoxic alkaloids from leaves of *Pilea* aff. Martinii. Planta Med. 85, 496–502. https://doi.org/10.1055/a-0826-0483.
- Hart, N.K., Johns, S.R., Lamberton, J.A., 1968. Minor akaloids of *Boehmeria platyphylla* Don. (Family Urticaceae): isolation of cryptopleurine and a new secophenanthroquinolizine alkaloid. Aust. J. Chem. 21, 2579–2581.
- Hartman, D.A., Pontones, M.E., Kloss, V.F., Curley, R.W., Robertson, L.W., 1988. Models of retinoid metabolism: microbial biotransformation of α-Ionone and β-Ionone. J. Nat. Prod. 51, 947–953. https://doi.org/10.1021/np50059a022.
- Hoffmann, J.J., Luzbetak, D.J., Torrance, S.J., Cole, J.R., 1978. Cryptopleurine, cytotoxic agent from *Boehmeria Caudata* (Urticaceae) and *Cryptocarya laevigata* (Lauraceae). Phytochemistry 17, 1448. https://doi.org/10.1016/S0031-9422(00)94617-X.
- Hu, Z., Wang, Y., 2013. Chemical constituents from the leaves of *Premna microphylla* Turcz. J. Chinese Pharm. Sci. 22, 431–434. https://doi.org/10.5246/ icps.2013.05.063.
- Ito, N., Etoh, T., Hagiwara, H., Kato, M., 1997. Novel synthesis of degradation products of carotenoids, megastigmatrienone analogues and blumenol-A. J. Chem. Soc. Perkin Trans. I 1 (4), 1571–1580. https://doi.org/10.1039/a607028k.
- Jia, X., Zhao, H., Du, C., Tang, W., Wang, X., 2020. Possible pharmaceutical applications can be developed from naturally occurring phenanthroindolizidine and phenanthroquinolizidine alkaloids. Phytochem. Rev. 3, 1–24. https://doi.org/ 10.1007/s11101-020-09723-3.
- Kim, S., Lee, T., Lee, E., Lee, J., Fan, G., Lee, S.K., Kim, D., 2004. Asymmetric Total Syntheses of (-)-Antofine and (-)-Cryptopleurine using (R)-(E)-4-(Tributylstannyl) but-3-en-2-ol. J. Org. Chem. 69, 3144–3149. https://doi.org/10.1021/j0049820a.
- Krmpotic, E., Farnsworth, N.R., Messmer, W.M., 1972. Cryptopleurine, an active antiviral alkaloid from *Boehmeria cylindrica* (L.) sw. Urticaceae). J. Pharm. Sci. 61, 1508–1509. https://doi.org/10.1002/jps.2600610945.
- Luo, Y., Liu, Y., Luo, D., Gao, X., Li, B., Zhang, G., 2003. Cytotoxic alkaloids from Boehmeria siamensis. Planta Med. 69, 842–845.

- Lykkeberg, A.K., Christensen, J., Budnik, B.A., Abe, F., Jaroszewski, J.W., 2002. In vitro cytotoxic activity of phenanthroindolizidine alkaloids from *Cynanchum vincetoxicum* and *Tylophora tanakae* against drug-sensitive and multidrug-resistant Cancer cells. J. Nat. Prod. 65, 1299–1302. https://doi.org/10.1021/np0106384.
- Machida, K., Kikuchi, M., 1996. Norisoprenoids from Viburnum dilatatum.
 Phytochemistry 41, 1333–1336. https://doi.org/10.1016/0031-9422(95)00790-3.
 Manggau, M.A., Andriani, F., Murdifin, M., Nurdin, W.B., Yulianti, R., Usmar, Sutriadi, S., 2018. In vitro study of the alkaloid anticancer compound from makassar
- medicinal plants Boehmeria virgata linn. Int. J Pharm Sci Rev Res 49 (1), 77–81. Mori, K., 1974. Syntheses of optically active grasshopper ketone and dehydrovomifoliol as a synthetic support for the revised absolute configuration of (+)-abscisic acid. Tetrahedron 30, 1065–1072. https://doi.org/10.1016/S0040-4020(01)97270-9.
- Oyarzún, M.L., Garbarino, J.A., Gambaro, V., Guilhem, J., Pascard, C., 1986. Two triterpenoids from *Boehmeria excelsa*. Phytochemistry 26, 221–223. https://doi.org/ 10.1016/S0031-9422(00)81516-2.
- Rahim, A., Saito, Y., Miyake, K., Goto, M., Chen, C.-H., Alam, G., Morris-Natschke, S., Lee, K.-H., Nakagawa-Goto, K., 2018. Kleinhospitine e and cycloartane triterpenoids from *Kleinhovia hospita*. J. Nat. Prod. 81, 1619–1627. https://doi.org/10.1021/acs. jnatprod.8b00211.
- Rahim, A., Saito, Y., Fukuyoshi, S., Miyake, K., Goto, M., Chen, C.-H., Alam, G., Lee, K.-H., Nakagawa-Goto, K., 2020. Paliasanines a–e, 3,4-Methylenedioxyquinoline alkaloids fused with a Phenyl-14-oxabicyclo[3.2.1]octane unit from *Melochia umbellata* var. *Deglabrata*. J. Nat. Prod. 83, 2931–2939. https://doi.org/10.1021/acs.jnatprod.0c00454.
- Saifah, E., Kelley, C.J., Leary, J.D., 1983. Constituents of the leaves of Cissus rheifolia. J. Nat. Prod. 46, 353–358. https://doi.org/10.1021/np50027a010.
- Saito, Y., Kobayashi, Y., Yoshida, N., Goto, M., Nakagawa-Goto, K., 2021. Synthesis of thio-lignan analogues, bioequivalent salvinal without unfavored aldehyde. Cite This J. Org. Chem 86, 7092–7106. https://doi.org/10.1021/acs.joc.1c00348.
- Seifert, K., Unger, W., 1994. Insecticidal and fungicidal compounds from Isatis tinctoria. Zeitschrift für Naturforsch. C 49, 44–48. https://doi.org/10.1515/znc-1994-1-208.
- Semwal, D.K., Rawat, U., Semwal, R., Singh, R., Krishan, P., Singh, M., Singh, G.J.P., 2009. Chemical constituents from the leaves of *Boehmeria rugulosa* with antidiabetic and antimicrobial activities. J. Asian Nat. Prod. Res. 11, 1045–1055. https://doi. org/10.1080/10286020903352526.
- Song, M.-C., Yang, H.-J., Jeong, T.-S., Kim, K.-T., Baek, N.-I., 2008. Heterocyclic compounds from *Chrysanthemum coronarium* L. And their inhibitory activity on hACAT-1, hACAT-2, and LDL-oxidation. Arch. Pharm. Res. 31, 573–578. https://doi. org/10.1007/s12272-001-1195-4.
- Stærk, D., Christensen, J., Lemmich, E., Duus, J.Ø., Olsen, C.E., Jaroszewski, J.W., 2000. Cytotoxic activity of some phenanthroindolizidine N -Oxide alkaloids from *Cynanchum vincetoxicum*. J. Nat. Prod. 63, 1584–1586. https://doi.org/10.1021/ np0003443.
- Suzuki, H., Aoyagi, S., Kibayashi, C., 1995. Asymmetric total synthesis of (R)-(-)-Cryptopleurine and (R)-(-)-Julandine via highly enantioselective amidoalkylations with N-Acylhydrazonium salts. J. Org. Chem. 60, 6114–6122. https://doi.org/10.1021/j000124a025.
- Takemoto, T., Miyasi, T., Kusano, G., 1975. Boehmenan, a new lignan from the roots of Boehmeria tricuspis. Phytochemistry 14, 1890–1891. https://doi.org/10.1016/0031-9422(75)85330-1.
- Wardihan, Rusdi, M., Alam, G., Lukman, Manggau, M.A., 2013. Selective Cytotoxicity Evaluation in Anticancer Drug Screening of *Boehmeria virgata*(Forst) Guill Leaves to. Dhaka Univ. J. Pharm. Sci. 12, 87–90.
- Yamashita, M., Saito, Y., Rahim, A., Fukuyoshi, S., Miyake, K., Goto, M., Nakagawa-Goto, K., 2020. Novel furoquinolinones from an Indonesian plant. Lunasia amara. Tetrahedron Lett 61. https://doi.org/10.1016/j.tetlet.2020.151861.